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Supplementary Methods 
 
 
Immunoprecipitation and Immunoblotting: The antibodies used in these studies were: 
Cleaved caspase-3, ERK1/2, p-ser473-AKT, p-thr308-AKT, p-ser70-4EBP1, Bcl-xL (Cell 
Signaling Technology; Beverly, MA). Bax, Bcl-2, and Mcl-1 (PharMingen; San Diego, CA). 
Poly(ADP-ribose) Polymerase (PARP) (Biomol Research Laboratories, Plymouth Meeting, 
PA). AIF, cytochrome c, Bak, AKT (Santa Cruz Biotechnology, Santa Cruz, CA). Bim, and -
tubulin (Calbiochem).  
 
Mutation analysis:  Primary AML samples were analyzed for mutations in 50 cancer associated 
genes using Next Generation Sequencing (NGS). Briefly, libraries for each sample were 
generated from 10 ng of dsDNA using Ion AmpliSeqTM Cancer Hotspot Panel v2 (Life 
Technologies, Carlsbad, CA). This panel consists of 207 amplicons covering near 2,800 
COSMIC mutations in 50 cancer-associated genes: ABL1, AKT1, ALK, APC, ATM, BRAF, 
CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, 
FGFR2, FGFR3, FLT3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, 
KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, 
PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL. Sequencing was 
conducted on Ion 316TM chips and run on the Ion Torrent PGM instrument using the Ion PGM™ 
Sequencing 200 kit v2 (Life Technologies) following the manufacturer’s recommendations. 
 
Generation of Ba/F3 mutants: Ba/F3 cells were purchased from the DSMZ and were 
maintained in RPMI-1640 medium with 10% FBS and 2 ng/ml of murine IL-3. Ba/F3 cells 
carrying FLT3 mutations were generated as follow: Total RNA was extracted from the MV4-11 
cells using the RNeasy kit (Qiagen) and cDNA was synthetized using AccuScript High-Fidelity 
Reverse Transcriptase (Agilent Technologies). FLT3-ITD was amplified and cloned into 
pLVX-IRES-ZsGreen1 vector (clontech) using PCR In-Fusion HD cloning kit (Clontech). 
FLT3-F691L point mutation was introduced into FLT3-ITD cDNA using the QuikChange Site-
Directed Mutagenesis Kit (Stratagene). All inserts were fully sequenced using primer walking 
DNA sequencing (Eurofins MWG Operon Huntsville, AL). Lentiviruses carrying FLT3-ITD or 
FLT3-ITD-F691L were generated and used to infect Ba/F3 wild type cells as previously 
described 1. Following 3 days of culture in the presence of IL-3, IL-3 was removed and cells 
were cultured for an additional 3 weeks. The cell population selected was confirmed for GFP 
expression by flow cytometry in association with FLT3 mutant expression and increased 
STAT5 phosphorylation by Western blot analysis.   
 
Statistical analysis: The significance of differences between experimental conditions was 
determined using the Student’s t test for unpaired observations. Survival rates were analyzed by 
Kaplan–Meyer and comparisons of survival curves and median survival were analyzed by 
logrank test. Animals that deceased due to causes unrelated to disease or treatment toxicity (e.g., 
sacrifice) were considered censored for survival analysis. 
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Legends to Supplementary Figures 
Supplementary Figure 1. Inhibition of Bcl-2 or Bcl-2/Bcl-xL markedly enhances INK128 
lethality in AML cells. A) U937 cells displaying tet-inducible dual knock-down of Bcl-2 and Bcl-
xL were left untreated or pre-treated with 1 g/ml doxycycline (Dox) for 48 hr, then exposed to 
the designated concentration of INK128 or Rapamycin for 7 hr, after which cell growth and 
viability was assessed using the Cell-Titer-Glo luminescent assay. B) NOD/SCID mice were 
injected via tail vein with U937 cells exhibiting tet-inducible Bcl-2/Bcl-xL dual knock-down and 
expressing luciferase. Mice were fed either with regular or doxycycline-supplemented pellets (200 
mg/kg, Bio-Serv, Frenchtown, NJ). At the designated intervals, mice were imaged using the IVIS 
200 system. U937 (C), and MV4-11 (D) cells were treated with INK128 and ABT-737 alone or in 
combination for 24 hr after which cell growth and viability was assessed using Cell-Titer-Glo 
luminescent assay and median dose effect analysis was performed using CalcuSyn software. The 
agent concentrations used were: For U937 cells, ABT-737: 250, 500, 750, 1000 nM; INK128: 100, 
200, 300, and 400 nM. For MV4-11, ABT-737: 5, 10, 15, and 20 nM; INK128: 50, 100, 150, and 
200 nM. E) MV4-11, MOLM-13, and KG-1 cells were treated with INK128 (100 nM for MV4-
11 and MOLM-13 cells; 200 nM for KG-1 cells) ± ABT-199 (10 nM for MV4-11 and MOLM-13 
cells; 500 nM for KG-1 cells) for 24 hr, after which the extent of cell death was assessed by 
Annexin V/PI staining assay. Error Bars: S.D of 3 independent experiments; *, p < 0.05 for 
combined treatment compared to either agent alone. 
Supplementary Figure 2. Activity of FLT3 inhibitors sorafenib or quizartinb in Ba/F3 cells 
expressing FLT3-ITD or FLT3-ITD F691L mutations. Wild type Ba/F3 cells or Ba/F3 cells 
expressing FLT3-ITD or FLT3-ITD F691L were treated with the designated concentrations of 
sorafenib or quizartinib for 24 hr after which cell growth and viability were assessed using the 
CellTiter-Glo luminescent assay. Values represent the means for 3 independent experiments ± S.D.  
Supplementary Figure 3. Mcl-1, Bcl-2, or Bcl-xL oppose INK128/ABT-737-mediated cell 
death in AML cells. A) MV4-11 cells were exposed to 10 nM ABT-737 and 100 nM INK128 
individually or together for 24 hr, after which cells were lysed and protein lysates subjected to 
Western blot analysis. B) U937 cells ectopically expressing Mcl-1 or their empty vector control 
counterparts (pCEP) were exposed to 200 nM INK128 ± 500 nM ABT-737 for 24 hr, after which 
cell growth and viability were assessed using the CellTiter-Glo luminescent assay. Values 
represent the means for 3 independent experiments ± S.D. C) Western blot analysis in untreated 
U937 cells ectopically expressing Bcl-2, Bcl-xL or the empty vector pREP. D) Assessment of cell 
growth and viability using the CellTiter-Glo Luminescent assay following cell exposure to 200 
nM INK128 ± 500 nM ABT-737 for 24 hr. Error Bars: S.D of 3 independent experiments; *, p < 
0.01 in each case.  
Supplementary Figure 4. Modulation of mTOR inhibitor/ABT-737 anti-leukemia activity by 
AKT. A-B) U937 or MV4-11 cells were exposed to the designated concentrations of rapamycin 
or INK128 for 4 hr after which cell were lysed and protein lysates were subjected to Western blot 
analysis. C) Assessment of cell growth and viability using the CellTiter-Glo Luminescent assay in 
MV4-11 cells following 24 hr exposure to the indicated agents. The doses used in this study were: 
10 nM ABT-737; 100 nM INK128; 100 nM rapamycin; and 2 M AKTi (AKT inhibitor VIII). 
Values represent the means for at least 3 independent experiments ± S.D. *, p < 0.05. D) Blots 
(from Figure 8C) were quantified using Image Studio Software (Li-Cor Biosciences), and results 
were normalized for ERK1/2 loading controls. The data shown represent the means for 2 sets of 
animals.  
 
Supplementary Figure 5. Effect of combined treatment with INK128 and ABT-737 on animal 
weight. NOD/SCID gamma mice bearing MV4-11-derived systemic xenograft were treated with 
INK128 (0.5 mg/kg) and ABT-737 (80 mg/kg) alone or in combination for the designated 
intervals, after which animal body weights were measured. Data involve at least 5 mice/condition. 
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